Adaptive Biotechnologies raises 2026 revenue outlook and targets profitability

Adaptive Biotechnologies has increased its 2026 revenue forecast for MRD (minimal residual disease) to $260 million-$270 million, while also aiming for positive adjusted EBITDA and free cash flow by the end of 2026. The updated outlook reflects the company's confidence in its growth trajectory and financial health.